key: cord-0869622-9p1dehhv
authors: Rist, Pamela M.; Sesso, Howard D.; Manson, JoAnn E.
title: Innovation in the design of large-scale hybrid randomized clinical trials
date: 2020-10-18
journal: Contemp Clin Trials
DOI: 10.1016/j.cct.2020.106178
sha: e9196e7fe4e218c5f7cc58cc822b8389ce38e7ae
doc_id: 869622
cord_uid: 9p1dehhv

nan

to provide information on both effectiveness and efficacy. In the absence of an interaction between the interventions, the factorial design allows for testing two or more interventions independently and jointly, at minimal incremental cost ( Figure 2 ). This pragmatic approach to large-scale prevention trials allows investigators to answer pressing scientific questions feasibly and cost-efficiently. In this commentary, we focus on the key aspects of the hybrid large-scale RCT design and efficiency featuresembedded patient recruitment, remote collection of biospecimens, in-person clinicbased assessments, and the combination of remote and in-person data collectionwhich have been successfully implemented in the recently completed VITAL 4-6 and the ongoing COSMOS trials. 7 Embedded Recruitment Sources Large-scale RCTs present challenges for trialists given the number of participants that must be recruited, screened, enrolled, and randomized within a reasonable timeframe, as well as the need to maintain high adherence and retention rates long term. Therefore, recruitment from ongoing large-scale cohorts, registries, or other accessible databases or resources, i.e. targeted or embedded recruitment, may reduce recruitment costs, accelerate start-up times, and shorten enrollment phases while allowing trials to meet pre-specified sample size estimates and event rates of the primary outcomes of interest.

Our conduct of large-scale, long-term, predominantly mail-based primary and secondary prevention trials since the 1980s has provided valuable perspectives on the importance of targeted and embedded recruitment sources. The Physicians' Health Study (PHS) I, a mail-based 2x2 factorial trial testing aspirin and beta-carotene in the J o u r n a l P r e -p r o o f primary prevention of CVD and cancer, recruited among 261,248 U.S. male physicians aged to 40 and 84 years identified from American Medical Association mailing lists. This study population was chosen because it was expected that physicians, due to their medical knowledge, would be able to provide informed consent regarding the risks and benefits of aspirin, provide high-quality data on endpoints, and understand the clinical trial requirements. 8, 9 Ultimately, 22,071 (8.4% of those initially contacted) male physicians were randomized into PHS I. The Women's Health Study (WHS), another mail-based trial, tested aspirin, beta-carotene, and vitamin E (in a 2x2x2 factorial design) for the primary prevention of CVD and cancer and similarly used existing mailing lists of female health professionals from state nursing boards and other health organizations to identify 1,757,247 U.S. female health professionals aged ≥45 years. [10] [11] [12] WHS randomized 39,876 (2.3% of those initially contacted) women nationwide. The 2.3% randomization yield for WHS required much greater financial and organizational resources than the 8.4% randomization yield for PHS I.

Despite the successes of targeted recruitment using health professionals for large-scale RCTs such as the PHS and WHS, the recruitment yield would be expected to be significantly lower for similarly sized, more generalizable prevention trials in the broader population. As a result, there was a need to innovate recruitment strategies to meet the scientific goals of a large-scale RCT in the general population. We discuss two strategies for targeted and embedded recruitment for cost-effective, pragmatic largescale RCTs.

First, existing study participants and other patient data sources can allow investigators to quickly and cost-effectively identify large numbers of potentially eligible J o u r n a l P r e -p r o o f participants for RCT recruitment. Current observational study participants and prior clinical trial participants have already demonstrated interest in participating in healthrelated research and have available data to allow investigators to identify individuals more likely to meet inclusion criteria. For example, the nationwide VITAL trial identified prior WHS trial participants still actively followed for post-trial observational follow-up, of whom 12.6% were willing, eligible, completed a placebo run-in, and were randomized into VITAL. Thus, nearly 10% of the total VITAL study population could be efficiently recruited through an ongoing parallel cohort. In contrast, recruitment efforts in the general population resulted in much lower randomization yields for VITAL, with 0.3% of those contacted through various targeted mass mailings and community-based efforts ultimately randomized.

The COSMOS trial had a similar recruitment experience. We recruited participants from the ongoing Women's Health Initiative (WHI) who met eligibility criteria based on existing WHI data. Among WHI participants invited into COSMOS, 6.4% were eligible, willing, and successfully completed a placebo run-in and were randomized into COSMOS. We also contacted non-randomized VITAL participants who responded to VITAL enrollment questionnaires but were unwilling or ineligible to participate in VITAL, resulting in a randomization rate of 2.9%. In contrast, nationwide mass mailings to ageeligible adults resulted in a lower randomization rate of 0.36%. Low randomization yields for general population mail-based RCTs is unfortunately common, and pilot studies to project recruitment yields are critically important for RCT planning. 13 Smallerscale RCTs can better leverage ongoing larger studies for patient recruitment. For example, a recent trial testing a polypill for cardiovascular disease prevention recruited J o u r n a l P r e -p r o o f from 1,202 participants assessed for eligibility from the Southern Communities Cohort Study, of whom 303 (25.2%) were randomized. 14 While recruiting from ongoing studies can improve randomization rates, there are challenges to consider. The investigators from the new RCT and existing study must work together on data collection, data harmonization, and data access. In addition, investigators must be mindful of the burden placed on participants by enrolling in two simultaneous studies and seek to minimize duplicate questionnaires and assessments.

There is also concern that individuals who choose to participate in one or more studies may be healthier and more motivated than the population to whom the study results would be generalized. Research networks such as PCORnet (https://pcornet.org/clinical-research-network/) also offer opportunities to leverage existing resources and to perform collaborative RCTs across multiple institutions, as was done in the ADAPTABLE trial. 21 EHRs are another promising source of potential trial participants for a wide variety of research goals. The availability of demographic and health information allows investigators to identify potentially eligible participants with more precision than conventional methods based on targeted mass mailing lists or personal or professional interests. 22 However, investigators must still determine the best search strategies and understand potential limitations of EHR data; strategies are particularly complex when working across multiple EHR systems. For example, an initial set of ICD-9 and ICD-10 codes used by the ADAPTABLE trial to identify patients with established atherosclerotic CVD did not adequately capture the study population of interest. By working with participating health systems, investigators were able to create computer algorithms termed "computable phenotypes" to identify their population of interest more appropriately. 23 Second, it is important for hybrid large-scale RCTs to proactively identify diverse populations for targeted and embedded recruitment. Recruitment of diverse participants for any RCT can be challenging and is magnified in large pragmatic RCTs conducted remotely. The goal of the VITAL trial was to randomize at least 20% (n=5,000) African-Americans among 25,000 trial participants due to their lower vitamin D levels. 24, 25 J o u r n a l P r e -p r o o f Recruitment of African Americans and other specific population groups into clinical trials may require coordination and building relationships in trusted community settings and with staff (e.g. community health centers). 26 To achieve its recruitment goal, VITAL trial planning required additional embedded recruitment strategies including mass mailings enhanced for racial/ethnic diversity, community-based strategies in large urban centers, and follow-up requests to minority non-respondents. Based upon our experience and equally applicable to other trialists interested in conducting hybrid RCTs, several options are available to coordinate biospecimen collection on a local, regional, or national scale, as described below.

For remote venous blood collection, participants can have their blood drawn and sent back on their own, typically through their healthcare provider. Reimbursement for any costs from their own healthcare provider may be necessary, and on average tend to be modest per participant. This approach was successfully pioneered and implemented by early hybrid RCTs such as PHS 27, 28 and WHS, 29 but these trials were among health professionals with greater access to phlebotomy services than the general population.

Therefore, for greater flexibility for those unable to have blood drawn on their own, investigators can coordinate either with local or national companies that provide on-site phlebotomy services (e.g. Quest Diagnostics has ~2000 centers nationwide), or with J o u r n a l P r e -p r o o f satellite clinics of many hospitals and health care centers. It is imperative for service coverage to reflect the geographic representation of trial participants. These costs are on average greater than participants getting blood drawn by their own healthcare providers but can still be reasonable. However, not all trial participants can reliably access on-site phlebotomy services. Therefore, a final option is for blood to be drawn at the participant's residence by a company that provides local or national mobile phlebotomy services. This may come at a steeper price to cover time and travel by the phlebotomist but has an important advantage that all participants have the opportunity to provide biospecimens for a blood subcohort that is representative of the overall trial population. The cost of obtaining blood specimens depends on many factors and should be weighed carefully against the expected participation rate among treatment participants, as determined by pilot studies.

Remote biospecimen collection is not confined to venous blood, which requires a phlebotomist for sample collection. Many other types of biospecimenssaliva, 30 buccal cells, 31 fecal samples, 32 toenail clippings, 33 urine, 34 and dried blood spots using finger pricks, among othersdo not necessarily require healthcare provider assistance and can be accomplished by trial participants on their own with more detailed instructions plus available staff to answer any questions. Finally, on-site or in-home clinic visits can include in-person clinical assessments vital to the hybrid design, such as height, weight, waist and hip circumference, seated blood pressure, 24-hour ambulatory blood pressure, physical function assessments, and other key clinical variables. The potential success of any biospecimen collection as part of a hybrid large-scale RCT is closely linked to the dedication and engagement of the trial population. weight, waist and hip circumference, seated blood pressure, physical performance, fasting blood and urine samples, 2-hour oral glucose tolerance testing, spirometry, bone mineral density and adiposity assessments (dual-energy x-ray absorptiometry) testing, 2D-echocardiography, and structured cognitive and mood assessments. 35 In VITAL, multiple ancillary studies allowed testing of a diverse array of clinical endpoints relevant to the interventions, leveraging both the parent trial and the CTSC visits (Table 1) .

As would be expected, the clinic-based subcohort of a hybrid RCT may be healthier than the overall trial cohort due to the ability to attend a detailed clinical visit. 35 However, the subcohort should retain the same high internal validity as the overall trial (if the distribution of characteristics is balanced by treatment arm) while examining the hypothesized mechanistic underpinnings of the primary and secondary trial outcomes.

The randomization scheme for the clinic-based subcohort should match that for the overall RCT with sensitivity analyses comparing the effect of the randomized intervention for the overall trial cohort versus the clinic-based (and biospecimen) subcohort.

Our experiences utilizing a hybrid RCT design with remote intervention delivery to all participants coupled with detailed biospecimen and in-person clinic assessments For interventions that can be tested using a pragmatic and remote-delivery design, these approaches would be among the many promising and cost-efficient options for trialists to consider when planning future RCTs.

J o u r n a l P r e -p r o o f 

Adaptive Designs for Clinical Trials

Pragmatic Trials

Controlled Trials in Health Insurance Systems

Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer

Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease

rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease

Large-scale randomized clinical trials of bioactives and nutrients in relation to human health and disease prevention -Lessons from the VITAL and COSMOS trials

Lack of Effect of Long-Term Supplementation with Beta Carotene on the Incidence of Malignant Neoplasms and Cardiovascular Disease

Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial

Beta-carotene supplementation and incidence of cancer and cardiovascular disease: the Women's Health Study

A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women

Recruiting to a large-scale physical activity randomised controlled trial -experiences with the gift of hindsight

Polypill for Cardiovascular Disease Prevention in an Underserved Population

Assessing the Nationwide Impact of a Registry-Based Randomized Clinical Trial on Cardiovascular Practice

Embedding a randomized clinical trial into an ongoing registry infrastructure: Unique opportunities for efficiency in design of the Study of Access site For Enhancement of Percutaneous Coronary Intervention for Women (SAFE-PCI for Women)

Association of National Cancer Institute-Sponsored Clinical Trial Network Group Studies With Guideline Care and New Drug Indications

National Institutes of Health StrokeNet I

National Institutes of Health. NIH launches clinical trials network to test COVID-19 vaccines and other prevention tools

Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial

Epub 2020/03/19

Building the Partners HealthCare Biobank at Partners Personalized Medicine: Informed Consent, Return of Research Results, Recruitment Lessons and Operational Considerations

Computable Phenotype Implementation for a National, Multicenter Pragmatic Clinical Trial: Lessons Learned From ADAPTABLE

Vitamin D and African Americans

Vitamin D intakes by children and adults in the United States differ among ethnic groups

Recruitment and retention of participants in a pragmatic randomized intervention trial at three community health clinics: Results and lessons learned

Analgesic use and renal function in men

C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men

Women's Genome Health Study Working G. Rationale, design, and methodology of the Women's Genome Health Study: a genome-wide association study of more than 25,000 initially healthy american women

Collecting Saliva Samples by Mail

Feasibility of collecting buccal cell DNA by mail in a cohort study

Stability of the human faecal microbiome in a cohort of adult men

A Prospective Study of Toenail Trace Element Levels and Risk of Skin Cancer

Vitamin D and omega-3 trial to prevent and treat diabetic kidney disease: Rationale, design, and baseline characteristics

RECOVERY Collaborative Group. Effect of Dexamethasone in Hospitalized Patients with COVID-19 -Preliminary Report. medRxiv (preprint)